Skip to content Skip to footer

A Comprehensive Look at the Future of Hospital Acquired Disease Testing Market

The Global Hospital Acquired Disease Testing Market is projected to expand with a Compound Annual Growth Rate (CAGR) of 7.7% from 2023 to 2031, according to a detailed study by FutureWise Market Research.

Hospital-acquired infections (HAIs), also known as healthcare-associated infections, are potentially harmful diseases contracted by patients during their stay in a hospital or other healthcare facilities and result from a wide gamut of microorganisms such as bacteria, viruses, fungi, and parasites. HAIs pose a severe public health concern leading to prolonged hospital stays, increased healthcare costs and, in severe cases, escalating to disability or even death. Therefore, testing for these infections forms a crucial part of infection prevention and control programs across healthcare facilities.

Different methodologies like microbiology culture, serology, nucleic acid amplification tests (NAATs), and imaging studies aid in detecting HAIs. The choice of test hinges on the suspected type of infection and the patient’s clinical presentation.

The report published by FutureWise includes a comprehensive analysis of the Hospital Acquired Disease Testing Market trends influencing the market’s overall growth. This report will offer an in-depth study of the market share, regional insights, competitor analysis, and shed light on the key manufacturers active in this industry.

Government initiatives and hospital acquired infection control authorities are focusing on spreading awareness about hospital acquired infections and available treatments, driving demand for hospital acquired infection testing. This, coupled with the rise in drug-resistant bacteria and increasing incidences of hospital acquired infections, bolsters the market growth of hospital acquired infections testing.

Despite the positives, safety concerns about the reprocessed instruments being used in the hospitals act as a restraining factor for the market growth. Departments of Health and Human Services of the United States estimate annual costs ranging from $28.0 billion to $33.0 billion for preventing hospital acquired infections.

To reduce the burden of lengthy patient stays in hospitals, governments are initiating steps to lower the occurrence of hospital acquired infections in their respective countries.

According to FutureWise Market Research, the Hospital Acquired Disease Testing Market is expected to grow at a CAGR of 7.7% during 2023-2031.


Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]